Gilead Sciences (GILD) just released its second-quarter financial results, posting non-GAAP diluted earnings of $2.56 and revenues of $7.14 billion. Currently, GILD is a Zacks Rank #3 (Hold) and is up 2.44% to $76.00 per share in trading shortly after its earnings report was released.Gilead:Beat earnings estimates. Gilead reported GAAP diluted earnings of $2.33 per share and non-GAAP diluted earnings of $2.56 per share. Adjusting for stock option expenses, the company posted earnings of $2.51 per share, beating the Zacks Consensus Estimate of $2.11.Beat revenue estimates. The company saw revenue figures of $$7.141 billion, crushing our consensus estimate $6.359 billion.Total product sales came in at $7.05 billion for the quarter, while royalty, contract, and other revenues totaled $95 million. Revenues were down about 6.7% from the prior-year quarter.Antiviral product sales, which include sales of HIV, chronic hepatitis B (HBV), and chronic hepatitis C (HCV) products totaled $6.4 billion, down from $7.1 billion in the same period last year. The slump in this unit was due to lower sales of HCV products, while sales of HIV and HBV products actually grew year-over-year.Research and development expenses came in at about $864 million, which was down from $1.48 billion last year.Gilead updated its full-year guidance. The company now expects revenues in the range of $24 - $25.5 billion, up from its previously announced range of $22.5 - $24.5 billion.Here’s a graph that looks at Gilead’s recent earnings performance:Gilead Sciences, Inc. Price, Consensus and EPS Surprise Gilead Sciences, Inc. Price, Consensus and EPS Surprise | Gilead Sciences, Inc. QuoteGilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer.Check back later for our full analysis on GILD’s earnings report!Want more stock market analysis from this author? Make sure to follow @https://twitter.com/Ryan_McQueeney!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?'http':'https';if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+"://platform.twitter.com/widgets.js";fjs.parentNode.insertBefore(js,fjs);}}(document,"script","twitter-wjs"); on Twitter!The Hottest Tech Mega-Trend of AllLast year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaries," but that should still leave plenty of money for regular investors who make the right trades early.See Zacks' 3 Best Stocks to Play This Trend >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research